Character Biosciences Expands Leadership Team and Secures Additional Series B Financing to Advance AMD Pipeline

字节生物科学扩展领导团队并获得额外的B轮融资以推进AMD管线

September 22, 2025

2025年9月22日

Character Biosciences has announced four key leadership appointments alongside an expansion of its Series B financing. These developments are expected to accelerate the company's efforts in developing novel therapies for degenerative eye diseases, including age-related macular degeneration (AMD) and geographic atrophy (GA)..

字符生物科学宣布了四项关键的领导任命，并扩大了其B轮融资。这些进展预计将加速该公司在开发退行性眼病（包括年龄相关性黄斑变性（AMD）和地理萎缩（GA））的新疗法方面的努力。

Strengthening Leadership to Support Clinical Advancement

加强领导力以支持临床进步

Character Biosciences has expanded its executive team with the appointment of four senior leaders:

Character Biosciences通过任命四位高级领导人扩大了其执行团队：

• Robert Kim, MD, MBA – Chief Medical Officer

• 罗伯特·金，医学博士，工商管理硕士 – 首席医疗官

• Daniel Elgort, PhD – Chief Data & Analytics Officer

• 丹尼尔·埃尔戈特，博士 – 首席数据与分析官

• Josh Buddle – Head of Clinical Network and Longitudinal Research

• Josh Buddle – 临床网络与纵向研究主管

• Jessamyn Wead – Head of People

• 杰萨明·韦德 – 人事主管

These appointments are intended to support the company’s growing pipeline and clinical infrastructure as it moves its first therapeutic programs closer to clinical trials.

这些任命旨在支持公司不断增长的管道和临床基础设施，因为公司正在将其首个治疗计划推向临床试验。

Series B Financing Expansion to Support Pipeline Development

B轮融资扩展以支持管道开发

Earlier this year, Character Biosciences secured $93 million in Series B financing to advance its therapeutic candidates targeting vision-threatening diseases. The round was co-led by new investors aMoon and Luma Group, with participation from Bausch + Lomb and Jefferson Life Sciences. Existing investors Innovation Endeavors, Catalio Capital Management, S32, and KdT Ventures also contributed..

今年早些时候，Character Biosciences获得了9300万美元的B轮融资，以推进其针对威胁视力疾病的治疗候选药物。本轮融资由新投资者aMoon和Luma Group共同领投，博士伦（Bausch + Lomb）和杰斐逊生命科学（Jefferson Life Sciences）也参与其中。现有投资者Innovation Endeavors、Catalio Capital Management、S32和KdT Ventures亦有贡献。

The most recent expansion of this Series B round includes new backing from Sanofi Ventures, along with additional support from both new and existing investors.

本轮融资的最新进展包括来自赛诺菲风险投资公司的新支持，以及来自新投资者和现有投资者的额外支持。

Pipeline Focus: CTX114 and CTX203

管线聚焦：CTX114 和 CTX203

According to the company, proceeds from the Series B financing will be used to accelerate the development of two lead programs:

根据公司介绍，B轮融资的收益将用于加速两个主要项目的开发：

• CTX203:

• CTX203:

A lipid modulator aimed at preventing progression to advanced age-related macular degeneration (AMD).

一种旨在防止进展为晚期年龄相关性黄斑变性（AMD）的脂质调节剂。

• CTX114:

• CTX114:

A complement inhibitor developed for the treatment of geographic atrophy (GA), a severe form of AMD.

一种为治疗地图状萎缩（GA）而开发的补体抑制剂，GA是AMD的一种严重形式。

Leadership Perspective on Strategic Growth

领导力视角下的战略增长

Cheng Zhang, CEO of Character Biosciences, commented: 'These appointments and the additional funding mark an important moment for Character Bio as we advance our first therapeutic programs toward the clinic. The expanded leadership team and strong support from our investors strengthen our ability to deliver on our mission of transforming outcomes for patients with vision-threatening diseases.'.

Character Biosciences首席执行官张程评论道：“这些任命和额外的资金标志着Character Bio的一个重要时刻，因为我们正在将我们的首个治疗项目推向临床。扩充的领导团队和投资者们的强大支持增强了我们实现使命的能力，即为患有威胁视力疾病的患者改善治疗效果。”

Incoming Chief Medical Officer Dr. Robert Kim also shared his perspective: 'I am thrilled to join Character at such a pivotal time. Dry AMD is the next frontier in ophthalmology, and Character’s multidisciplinary approach has the potential to deliver treatments that truly address the unmet needs of patients.'.

即将上任的首席医疗官罗伯特·金博士也分享了他的看法：“我非常高兴能在这样一个关键时期加入Character。干性AMD是眼科领域的下一个前沿，而Character的多学科方法有潜力提供真正满足患者未满足需求的治疗方案。”